Abstract
Background & Aims: Substantial heterogeneity in terminology used for eosinophilic gastrointestinal diseases (EGIDs), particularly the catchall term “eosinophilic gastroenteritis,” limits clinical and research advances. We aimed to achieve an international consensus for standardized EGID nomenclature. Methods: This consensus process utilized Delphi methodology. An initial naming framework was proposed and refined in iterative fashion, then assessed in a first round of Delphi voting. Results were discussed in 2 consensus meetings, and the framework was updated and reassessed in a second Delphi vote, with a 70% threshold set for agreement. Results: Of 91 experts participating, 85 (93%) completed the first and 82 (90%) completed the second Delphi surveys. Consensus was reached on all but 2 statements. “EGID” was the preferred umbrella term for disorders of gastrointestinal (GI) tract eosinophilic inflammation in the absence of secondary causes (100% agreement). Involved GI tract segments will be named specifically and use an “Eo” abbreviation convention: eosinophilic gastritis (now abbreviated EoG), eosinophilic enteritis (EoN), and eosinophilic colitis (EoC). The term “eosinophilic gastroenteritis” is no longer preferred as the overall name (96% agreement). When >2 GI tract areas are involved, the name should reflect all of the involved areas. Conclusions: This international process resulted in consensus for updated EGID nomenclature for both clinical and research use. EGID will be the umbrella term, rather than “eosinophilic gastroenteritis,” and specific naming conventions by location of GI tract involvement are recommended. As more data are developed, this framework can be updated to reflect best practices and the underlying science.
Original language | English |
---|---|
Pages (from-to) | 2474-2484.e3 |
Journal | Clinical Gastroenterology and Hepatology |
Volume | 20 |
Issue number | 11 |
DOIs | |
State | Published - Nov 2022 |
Funding
Funders | Funder number |
---|---|
Mapi Research Trust | |
Novartis Foundation for Biomedical Research | |
AMGEN | |
Nutricia, Abbott, and Mead Johnson | |
International Biometric Society | |
Office of Rare Diseases Research | |
Sanofi Genzyme | |
Receptos | |
Chugai Pharmaceutical | |
Eosinophilic Gastrointestinal Disease Researcheres | |
Takeda Pharmaceuticals U.S.A. | |
Australian Medical Council | |
Ferrer | |
Australian Renewable Energy Agency | |
Society for the Study of Theology | |
Rose Pharma | |
Calypso Biotech SA | |
School of Public Health, University of California Berkeley | |
Vifor Pharma | |
BioGaia | |
Falk Foundation | |
Falk Pharma International | |
Progenity Inc. | |
Shire | |
AbbVie | |
University of California, San Diego | |
UpToDate | |
Revolo Biotherapeutics | |
Shire/Takeda | |
Mochida Pharmaceutical | |
Sanofi-Aventis Deutschland | |
Eli Lilly and Company | |
Eosinophilic Family Coalition | |
Zeon Medical Inc. | |
Mitsubishi Tanabe Pharma Corporation | |
National Institutes of Health | |
British Society of Allergy and Clinical Immunology and Chair of Health Advisory Board of Allergy UK | |
Abbott Laboratories | |
Sanofi-Aventis AG | |
Vifor | |
National Institute of Allergy and Infectious Diseases | |
Adare Pharmaceuticals | |
National Health and Medical Research Council | |
International Foundation for Functional GI Disorders | |
Anatara Life Sciences | |
Janssen Pharmaceuticals | |
Regeneron/Sanofi | |
Daiichi-Sankyo | |
Bayer Fund | |
EosNetwork | |
JIMRO | |
Regeneron-Sanofi | |
LucidDx | |
Bristol-Myers Squibb | |
Abonia | |
GlaxoSmithKline | |
Sax Institute | |
Otsuka Pharmaceutical | |
Avant Foundation | |
Cincinnati Children's Hospital | |
Parexel/Calyx | |
AusEE | |
EA Pharma Co., Ltd. | |
National Center for Advancing Translational Sciences | |
Société des produits Nestlé | |
Sanofi/Regeneron | |
Sanofi | |
Pfizer | |
Nippon Kayaku | |
Celgene | |
AstraZeneca | |
Sungkyunkwan University School of Medicine | |
Dr. Falk Pharma | |
Cadila PharmIncaceuticals | |
Falk | |
Medtronic | |
Medis | |
Not added | 21K07833 |
Nepean Dyspepsia Index | 2021901692 |
CEGIR | U54 AI117804 |
American Partnership for Eosinophilic Disorders | U2CTR002818 |
Keywords
- Classification
- Delphi
- Eosinophilic Gastroenteritis
- Eosinophilic Gastrointestinal Disease
- Nomenclature